Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Schlüsselwörter
Abstrakt
Beschreibung
OBJECTIVES:
Primary
- Determine the clinical pharmacokinetic behavior of docetaxel with and without garlic tablets in patients with locally advanced or metastatic breast cancer.
- Determine the toxicity of this regimen in these patients.
Secondary
- Determine the incidence of enzyme and transporter polymorphism in patients treated with this regimen.
OUTLINE: This is a pilot, open-label study.
Patients receive docetaxel IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. On days 5-17 of course 1, patients receive oral garlic twice daily. Patients have the option of continuing garlic tablets as long as they remain on study.
PROJECTED ACCRUAL: A total of 9-12 patients will be accrued for this study within 6 months.
Termine
| Zuletzt überprüft: | 09/30/2006 |
| Zuerst eingereicht: | 03/07/2004 |
| Geschätzte Einschreibung eingereicht: | 03/08/2004 |
| Zuerst veröffentlicht: | 03/09/2004 |
| Letztes eingereichtes Update: | 06/17/2013 |
| Letztes Update veröffentlicht: | 06/19/2013 |
| Tatsächliches Startdatum der Studie: | 12/31/2003 |
| Voraussichtliches Abschlussdatum der Studie: | 09/30/2007 |
Zustand oder Krankheit
Intervention / Behandlung
Dietary Supplement: garlic
Drug: docetaxel
Phase
Zulassungskriterien
| Altersberechtigt für das Studium | 18 Years Zu 18 Years |
| Studienberechtigte Geschlechter | All |
| Akzeptiert gesunde Freiwillige | Ja |
| Kriterien | DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the breast - Incurable, locally advanced or metastatic disease for which therapy with docetaxel is a reasonable option - No documentation of progressive disease while on docetaxel within the past 2 months - Brain and/or leptomeningeal metastases are allowed only if all of the following criteria are met: - Asymptomatic on neurological examination, including after definitive radiotherapy - No corticosteroid therapy to control symptoms - Stable lesions - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age - 18 and over Sex - Male or female Menopausal Status - Not specified Performance status - ECOG 0-2 Life expectancy - At least 12 weeks Hematopoietic - Neutrophil count ≥ 1,200/mm^3 - Platelet count ≥ 100,000/mm^3 Hepatic - Bilirubin normal - ALT and AST ≤ 2 times ULN (3 times ULN with liver metastases) Renal - Creatinine normal OR - Creatinine clearance ≥ 60 mL/min Cardiovascular - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmias Gastrointestinal - No known gastric emptying disorders - No persistent diarrhea Other - No uncontrolled diabetes mellitus - No active infection - No prior grade 3 or 4 allergic reaction attributed to compounds of similar biological composition to garlic, docetaxel, or Tween 80 - No other concurrent uncontrolled medical condition that would preclude study participation - No psychiatric illness or social situation that would preclude study compliance - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception - Must be able to ingest oral medication - Lactic dehydrogenase ≤ 2 times ULN PRIOR CONCURRENT THERAPY: Biologic therapy - At least 3 weeks since prior immunotherapy - No concurrent immunotherapy - Trastuzumab (Herceptin®) allowed after the first course of therapy at the discretion of the primary physician - No concurrent pegfilgrastim Chemotherapy - See Disease Characteristics - At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) - No other concurrent chemotherapy Endocrine therapy - See Disease Characteristics - At least 2 weeks since prior hormonal therapy - No concurrent hormonal therapy - No concurrent megestrol during the first course of study treatment Radiotherapy - See Disease Characteristics - At least 3 weeks since prior radiotherapy - No concurrent radiotherapy Surgery - Not specified Other - More than 30 days (or 5 half-lives) since prior investigational therapy - No concurrent aprepitant (Emend®) - No concurrent or oral tetrahydrocannabinol (Marinol®) during the first course of study treatment - No concurrent combination antiretroviral therapy for HIV-positive patients - No other concurrent investigational or anticancer medications - No concurrent antiepileptic therapy - No concurrent immunosuppressants - No other concurrent herbal therapies during the first month of study participation - No concurrent grapefruit juice during the first month of study participation - No concurrent administration of the following: - Alprazolam - Cyclosporine - Diltiazem - Dofetilide - Erythromycin - Fluvoxamine - Itraconazole - Ketoconazole - Quinine - Hypericum perforatum (St. John's wort) - Tacrolimus - Theophylline - Warfarin - Zolpidem |
